Diflucan snagged as China tightens imported drug oversight
This article was originally published in Scrip
Despite its long-term market experience in China, Pfizer's first lesson of 2014 in the country is ironically all about compliance with local regulations. The US giant's antifungal drug Diflucan (fluconazole injection) has been suspended from entering the country by China's Food and Drug Administration (CFDA).
You may also be interested in...
The road to China's health-care market, once seen to be paved with gold by many medtech companies, is presenting more obstacles than before as a result of increased local competition and challenging policies. Multinationals and start-ups attending the recent China Healthcare Investment Conference discussed ways in which the medtech industry could continue to capitalize on this market's potential.
China is pushing ahead with initiatives in the precision medicine area, where it sees targeted diagnosis and treatment as particularly valuable in areas such as oncology, diabetes and cardiovascular disorders.
The China Food and Drug Administration has released the final version of its biosimilars guideline1.